Lumos touts cost savings for point-of-care infection test

By LabPulse.com staff writers

October 7, 2021 -- Lumos Diagnostics is highlighting clinical results that suggest its FebriDx point-of-care test to guide antibiotic treatment in patients with respiratory infections could save $2.5 billion annually in healthcare costs.

FebriDx is a finger-stick blood test that distinguishes bacterial from viral acute respiratory infections. The study, published September 30 in the Journal of Health Economics and Outcomes Research, found that FebriDx had a sensitivity of 95% to detect bacterial infections and a negative predictive value of 99% to rule out these infections.

The potential cost savings FebriDx could offer are based on a study performed by Avalon Health Economics that uses data from 2010 to 2020 and takes into consideration the cost of antibiotic treatment, antibiotic-resistant infections, antibiotic-related adverse events, and point-of-care testing on a national level, Lumos said.

Antibiotic use can be problematic, according to the research, which noted the following:

  • Of more than 150 million U.S. outpatient and emergency department visits for acute respiratory infections annually, half of antibiotics prescribed are medically unnecessary.
  • 2.8 million antibiotic-resistant infections occur annually in the U.S., according to the Centers for Disease Control and Prevention (CDC).
  • Outpatient settings are key to good "antibiotic stewardship": Between 2010 and 2015, outpatient settings represented 59% of all antibiotic expenditures.

FebriDx has not yet been cleared by the U.S. Food and Drug Administration (FDA), although it is cleared and available in Europe, Canada, and Australia, Lumos said.

Lumos gets cash to expand reach of respiratory test
Lumos Diagnostics has received $1.5 million in series A funding from parent company Planet Innovation of Box Hill, Victoria, Australia.

Copyright © 2021 LabPulse.com

Last Updated ls 10/6/2021 3:51:18 PM